Published • loading... • Updated
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
endpoints.newsReposted by 
BizToc
BizTocAstraZeneca blames trial design for Phase 3 failure of bone disease drug
New details from AstraZeneca's failed Phase 3 trial of its enzyme replacement therapy for a genetic bone disease suggest the test missed its goals because of how the trial was composed, as the drugmaker seeks ...
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
